Terumo Cardiovascular Systems

ocs header image
optimizing cardiac surgery
e-mail usprint

Blood Management

Information provided on this website is not intended to make claims that the products are safe and effective for any use other than those explicitly described in the Instructions for Use. Clinicians should refer to the Instructions for Use or Owner's Manuals for complete information on the intended use of any product mentioned in this website.

CASE STUDY: High Flow, Low Prime Oxygenator Contributes to Blood Management Program
Jeffrey Wilson, CCP, describes how the perfusion team at St. Joseph Hospital Center achieved a significant reduction in prime volume using CAPIOX® RX Oxygenators and blood management strategies.
CASE STUDY: Bloodless Cardiac Surgery is a Team Sport
Ninety percent of patients weighing over 25 kilos have surgery without receiving blood at The Heart Center at Nationwide Children's Hospital in Columbus, Ohio. Read about its blood management program.
CASE STUDY: Bloodless Surgery for Pediatric Cardiac Surgery Patients
Dave Fitzgerald, CCP, describes how the INOVA Fairfax Hospital team has adopted Jehovahs Witnesses blood management strategies for all patients- adults and pediatric.
SYNOPSIS: European Team Outlines Benefits Of Minimized Perfusion Circuit
At the Optimizing Cardiac Surgery Symposium on March 5, 2010, Uwe Schönrock, CCP, Klinikum Braunschweig, shared the clinical benefits of his team's use of the ROCSafe™ Hybrid Perfusion System in 2,500 cases.
CASE STUDY: Pediatric Blood Management Program Optimal With 3-Year-Olds
Medical College of Georgia Health Children's Medical Center uses smaller tubing and oxygenator to eliminate 200 ml of prime volume to benefit three-year-old patients.
STUDY: Children's Hospital Studies New Oxygenator with Integrated Arterial Filter
Joseph Deptula, CCP, Children's Hospital, found that the CAPIOX® FX05 Oxygenator significantly reduced CPB prime volumes and surface area while reducing blood donor exposure; all without compromising patient safety.
STUDY: Pediatric Hospital Uses New Technology to Remove Gaseous Microemboli and Reduce Blood Usage
Nationwide Children's Hospital evaluated the CAPIOX FX Oxygenator with an integrated arterial filter and found it significantly reduced prime volume and GME.
SUMMARY: Blood Management: In 2008, everyone was talking about it. In 2009, everyone wants to do it.
In an interview,Timothy Hannon, MD, reviews the highlights from his presentation at the 2009 Optimizing Cardiac Surgery Symposia, focusing on the need for clinician education.
PROTOCOL: Fresenius C.A.T.S System Plasma Sequestration Protocol.
The plasma sequestration protocol and process to help reduce blood and platelet transfusions during CPB at Mission St. Joseph's Hospital in Asheville, NC.
NEW! CDROM: Prescription Oxygenation: Using data to improve blood management
Sean Murtha, CCP, discusses blood management results at Joe DiMaggio Children's Hospital in Hollywood, Florida during his Optimizing Cardiac Surgery Symposia presentation in Newport Beach, California in February 2010.
NEW! CDROM: The Inflammatory Response to CPB – Continued Clinical Challenges and Technological Opportunities
Terence Gourlay, PhD, shares blood management studies from the University of Strathclyde in Scotland during the Optimizing Cardiac Surgery Symposia in Newport Beach, California in February 2010.
SYNOPSIS: Reducing a patient's exposure to banked blood . . . priceless.
At the San Diego Optimizing Cardiac Surgery Symposium (February 2008), David Fitzgerald, CCP, Joseph Basha, CCP, Jim Patterson, CCP, and Brad Kulat, CCP presented cost savings resulting from blood management programs.
NEW! CDROM: Controlling SIRS: Can new technology impact outcomes?
Uwe Schonrock, CCP, discusses the use and results of a minimized circuit at Braunschweig Klinikum in Germany during his Optimizing Cardiac Surgery Symposia presentation in Newport Beach, California in February 2010.
CD-ROM: Blood Management: Are We Doing The Best We Can? The Proof Is In The Data
Sean Murtha, CCP, shares how clinical data is used to improve blood management programs at the Optimizing Cardiac Surgery Symposium in Orlando in May 2009.
CDROM: Optimizing Pediatric Circuit Design Utilizing Terumo® Advanced Perfusion System 1
Brad Kulat, CCP, presents the "Flying V" circuit configuration as a means to reduce prime and blood usage at the 2007 Optimizing Cardiac Surgery Symposia Series.
CD-ROM: CSI Perfusion: Discovering the Evidence for Effective Blood Management
David Fitzgerald, CCP, shares results from the blood management program at Inova Heart and Vascular Institute at the Optimizing Cardiac Surgery Symposium in Orlando in May 2009.
CD-ROM: Blood Management: In 2008, everyone was talking about it. In 2009, everyone wants to do it.
In his presentation at the 2009 Optimizing Cardiac Surgery Symposia, Timothy Hannon, MD, provides a realistic definition of blood management and a discussion of issues driving its growing adoption.
CDROM: Non-Pharmacologic Therapeutic Strategies for Reducing Complications of Cardiopulmonary Bypass
Serdar Gunaydin, MD, PhD, presents clinically significant results using XCoating™ and leukocyte filtration for high-risk patients at the May 2006 Optimizing Cardiac Surgery Symposium.
CDROM: Circuit Evolution and Patient Benefits
Ben Komorowski, CCP, shares the eight year evolution of the changes in his perfusion circuit at the Orlando 2006 Optimizing Cardiac Surgery Symposium.
CDROM: From Science to Clinical Practice: A Synergistic Approach to Reducing Blood Loss and the Inflammatory Response
David Fallen, CCP, discuss non-pharmacologic approaches to reducing bleeding and SIRS at the Optimizing Cardiac Surgery Symposium in May 2006.
CDROM: Benefits, Features and Results of Reduced Prime Circuits
Order a complimentary CDROM of the New Orleans 2005 Optimizing Cardiac Surgery Symposium (April 2005) to watch David Fallen, CCP's presentation on the use of reduced prime circuits.
ABSTRACT: Clinical Gaseous Microemboli Assessment of an Oxygenator with Integral Arterial Filter in the Pediatric Population. JECT 2009; 41:226-230. Preston TJ, et al.
The authors determined the CAPIOX® FX15 Oxygenator was as effective in gaseous microemboli removal as was the more traditional oxygenator.
ABSTRACT: Clinical Evaluation of the Terumo Capiox® FX05 Hollow Fiber Oxygenator with Integrated Arterial Line Filter; JECT 2009; 41:220-225. Deptula J, et al.
In a comparison study, the authors found the CAPIOX® FX05 Oxygenator offers good gas exchange capabilities and a low pressure drop along with the safety of an integrated arterial line filter.
ABSTRACT: Beneficial Effects of Modern Perfusion Concepts in Aortic Valve and Aortic Root Surgery. Perfusion 2009;24: 37-44, Kutschka, et al.
In this 170-patient study, the use of the ROCSafe™ Hybrid Perfusion System was found to reduce side effects of standard extracorporeal circulation.
ABSTRACT: A New Minimized Perfusion Circuit Provides Highly Effective Ultrasound Controlled Deairing. Artificial Organs. 2007 Mar; 31(3):215-220, Kutschka, et al.
This study compared a ROCSafe™ Hybrid Perfusion System to conventional perfusion circuit and results indicated that active venous deairing was significantly reduced compared to passive deairing on a conventional circuit.
ABSTRACT: Optimizing Circuit Design Using a Remote-mounted Perfusion System. JECT 2009;41:28-31. Kulat, et al.
In this 62-patient pediatric study, the authors found that use of remotely mounted pump heads resulted in reduced priming volumes and less exposure to banked blood.
ABSTRACT Implementation of the Continuous AutoTransfusion System (C.A.T.S) in Open Abdominal Aortic Aneurysm Repair: An Observational Comparative Cohort Study. Vascular and Endovascular Surgery, Feb-March 2008; Vol. 42, 32-39, Tawfick, W, et al.
In 187 patients, who underwent AAA, the authors found the Fresenius C.A.T.S system reduced the amount of blood transfused, was associated with reduced ICU and hospital stay, and was cost effective.
ABSTRACT: Bloodless Cardiac Surgery and the Pediatric Patient: A Case Study. Perfusion 2008; 23: 131-134. Ging, AL et al.
The authors present blood management strategies in which a 5.9 kg Jehovah's Witness patient underwent successful correction of a VSD without the use of transfusions.
ABSTRACT: Intraoperative Autotransfusion in Small Children: An In-vitro Investigation to Study its Feasability. Anesth Analg, April 1999; 88(4): 763-6. Booke, et al.
This in-vitro study demonstrates the ability of the Fresenius C.A.T.S System to produce high quality HCT independent of blood volume suggesting the feasability of IAT in small children.
ABSTRACT: A New Poly-2-Methoxyethylacrylate-Coated CPB Circuit Possesses Superior Platelet Preservation and Inflammatory Suppression Efficacy. Annals of Thoracic Surgery. 2004; 77:1678-1683 Ikuta T, et al.
This study compares the biocompatibility of PMEA-coated circuits to heparin-coated and non-coated circuits, focusing on platelet preservation and systemic inflammatory response.
ABSTRACT: Investigation of Blood Compatibility of PMEA-Coated Extracorporeal Circuits. Journal of Bioactive and Compatible Polymers, Vol 17, Sept 2002. Kocakulak M, et al.
In a study comparing PMEA-coated and uncoated oxygenators, the authors found greater retention of clotting factors and platelets and less post-op hemorrhaging when using PMEA-coated oxygenators.
ABSTRACT: Evaluation of a New Condensed Extracorporeal Circuit for Cardiac Surgery: A Prospective Randomized Clinical Pilot Study. Perfusion 2005; vol. 20, 91-99. Fransen, et al.
The authors noted an improvement in biocompatibility in a reduced prime circuit with X Coating over a traditional circuit with heparin-coating.
ABSTRACT: Emerging Technologies in Biocompatible Surface Modifying Additives: Quest for Physiologic CPB. Cardiovascular and Hematological Agents. 2004; Vol. 2:No 4. Gunaydin S, et al.
The authors compare surface coatings, including X Coating, in 155 CPB cases for chemical composition, biomaterial evaluation and clinical efficacy.
ABSTRACT: The CAPIOX RX05 Oxygenator: Pediatric Clinical Observations. Perfusion. 2003;18, 321-323, Tinius, et al.
The authors provide clinical observations on the use of the CAPIOX® BABY RX™ Oxygenator and reducing prime volume in neonate circuits.
ABSTRACT: Effects of New Polymer-Coated Extracorporeal Circuits on Biocompatibility During Cardiopulmonary Bypass. Artificial Organs, Volume 24, No 7, 2000. Saito, et al.
This study compares X Coating™ to heparin coating in reducing the release of bradykinin and leukocyte activation during CPB.
ABSTRACT: Biocompatibility of Poly (2-methoxyethylacrylate) Coating for Cardiopulmonary Bypass. Annals Thoracic Cardiovascular Surgery, 2003, Volume 9, No 1. Noguchi, et al.
The authors compare the biocompatibility of PMEA-coated and heparin-coated circuits by measuring several inflammatory markers. Results indicate PMEA-coated circuits are as biocompatible as heparin coated circuits.
ABSTRACT: How Effective are Cardiopulmonary Bypass Circuits at Removing Gaseous Microemboli? JECT:2002;34:34-39. Stump D, et al.
This paper demonstrates how the quantity of venous air passed through a circuit differs by circuit design and manufacturer under both VAVD and gravity conditions.
ABSTRACT: Clinical Evaluation of Poly (2-methoxyethylacrylate) in Primary Coronary Artery Bypass Grafting. JECT 2005;37:23-31. Vang SN, et al.
The study demonstrates that the use of X Coating™ compared to no coating results in lower WBC counts, less blood transfusions, and a cost savings of $83.41 per patient.
ABSTRACT: X Coating: A New Biopassive Polymer Coating. Canadian Perfusion Canadienne, Volume 11, No 2, June 2001. Schiel, et al.
This paper explains the mechanism and benefits of X Coating™.
ABSTRACT: Inflammatory Response to Cardiac Surgery and Strategies to Overcome It. Annals of Cardiac Anaesthesia 2004;7:113-128. Kapoor, et al.
A review of the inflammatory response including: mediators of the response, role of surgical stress, the pathogenesis of organ damage and strategies to limit or overcome the response.
ABSTRACT: Non-Pharmacologic Therapeutic Strategies for Reducing Complications of Cardiopulmonary Bypass. Filtration 2005; 1(2):95-106. Gunaydin S, et al.
This study of 225 patients undergoing CPB concludes that the use of circuits with leukocyte filtration and X Coatingâ?¢ provides clinically significant benefits for high risk patients.
ABSTRACT: Quality of Processed Blood for Autotransfusion. JECT March 2000; 32: 11-9. Shulman, et al.
The authors evaluate the quality of processed blood using several parameters and demonstrate that the C.A.T.S System has a high washout efficiency and produces consistently high HCT at high flow rates.
ABSTRACT: The Efficacy of Autologous Platelet Gel in Pain Control and Blood Loss in Total Knee Arthroplasty. International Orthopedics. April 2006. 10.1007/s00264-006-0174z. Gardner, et al.
This study indicates that the application of autologous platelet gel may lead to improved haemostasis, better pain control and a shortened hospital stay.
ABSTRACT: An Evidence-Based Review of the Practice of Cardiopulmonary Bypass in Adults: a Focus on Neurologic Injury, Glycemic Control, Hemodilution and the Inflammatory Response.   J Thorac Cardiovasc Surg2006;132:283-290. Shann KG, et al.
The authors, members of the International Consortium for Evidence-Based Perfusion, offer their first publication of evidence and recommendations on the practice of managing patients on CPB.
ABSTRACT: A Review of Leukofiltration in Cardiac Surgery: The Time Course of Reperfusion Injury may Facilitate Study Design of Anti-Inflammatory Effects. Perfusion 2002; 17: 53-62. Ortolano, et al.
The authors address the effects of systemic inflammatory response syndrome (SIRS) during CPB, and provide a review of leukocyte filtration literature.
ABSTRACT: Blood Separation with Two Different Autotransfusion Devices: Effects on Blood Cell Quality and Coagulation Variables. Int. J Artif Organs, Dec 1998; 2: 820-4. Rosalski, et al.
The authors compare the Fresenius C.A.T.S System with another device and found that C.A.T.S had a higher platelet recovery rate and higher platelet concentration.
ABSTRACT: Levels of Inflammatory Markers in the Blood Processed by Autotransfusion Devices during Cardiac Surgery Associated with Cardiopulmonary Bypass Circuit. Perfusion 2002; 17:117-123. Amand, et al.
This study evaluates the ability of several cell salvage devices to remove white cells. The C.A.T.S System and Haemonetics CS5 devices removed the highest percentage of white cells.
VIDEO: The Role of the Manufacturer, Technology, Clinical Practice and Arterial Filtration (12:09)
Dave Fallen, Clinical Support, Terumo CVS, describes the development process and GME removal testing for the CAPIOX FX Oxgenator with Integrated Arterial Filter. Presented at the 2009 AmSECT Perfusion Safety/Best Practices Conference.